The Board of Directors of GlaxoSmithKline Pharmaceuticals Ltd has approved Buyback of its Equity shares from the existing shareholders through the stock exchange route, at a price not exceeding Rs 800 per share within the limit of Rs 230.65 crore being 25 per cent of the total paid-up Equity Share Capital and Free Reserves of the Company.